Management of Diarrhea After Antibiotics

Assessment and Classification

Evaluate severity based on stool frequency, consistency, presence of blood, fever, abdominal pain/cramping, and signs of dehydration, and assess for risk factors: fever, orthostatic symptoms, weakness, abdominal pain, and nocturnal diarrhea, according to the Journal of Clinical Oncology 1
Classify as "uncomplicated" (mild symptoms without complicating factors) or "complicated" (moderate to severe symptoms with risk factors), as recommended by the Journal of Clinical Oncology 1
Consider C. difficile infection if symptoms include fever, abdominal pain, leukocytosis, or bloody diarrhea, as suggested by Clinical Microbiology and Infection 2

For persistent or severe symptoms, obtain stool samples for C. difficile toxin testing, as recommended by Clinical Microbiology and Infection 2 and Annals of Oncology 3
Consider bacterial culture for other pathogens (Salmonella, Shigella, Campylobacter), as suggested by Clinical Infectious Diseases 4 and Annals of Oncology 3
Evaluate for other causes including treatment-associated or paraneoplastic conditions, as recommended by Annals of Oncology 3

Ensure adequate fluid intake with clear liquids (8-10 glasses daily) and avoid lactose-containing products, alcohol, and high-osmolar supplements, as recommended by the Journal of Clinical Oncology 1
Consider a bland/BRAT (bread, rice, applesauce, toast) diet, as suggested by the Journal of the National Comprehensive Cancer Network 5
Use loperamide 2 mg every 2 hours (maximum 16 mg/day) for non-bloody diarrhea in adults, as recommended by Annals of Oncology 3
Consider bismuth subsalicylate for mild symptoms, as suggested by Clinical Infectious Diseases 4
For C. difficile-associated diarrhea, use oral vancomycin 125 mg four times daily for 10 days, as recommended by Clinical Microbiology and Infection 2
For severe C. difficile infection with signs of severe colitis, use vancomycin 125 mg four times daily, as suggested by Clinical Microbiology and Infection 2
Consider octreotide 500 μg three times daily subcutaneously if diarrhea is refractory to loperamide, as recommended by Annals of Oncology 3 and the Journal of the National Comprehensive Cancer Network 5

Immunocompromised patients should be evaluated more aggressively with a lower threshold for antimicrobial therapy, as recommended by Clinical Infectious Diseases 4
Recurrent C. difficile infection may require vancomycin with a tapered and pulsed regimen, as suggested by Clinical Microbiology and Infection 2

Use antibiotics judiciously, selecting narrow-spectrum agents when possible, as recommended by Clinical Microbiology and Infection 2

Reassess patients who do not respond to initial therapy within 24-48 hours, as recommended by Clinical Infectious Diseases 4
Consider alternative diagnoses including inflammatory bowel disease or irritable bowel syndrome for symptoms lasting ≥14 days, as suggested by Clinical Infectious Diseases 4

The American Society of Clinical Oncology recommends using loperamide as first-line therapy for moderate non-infectious diarrhea after excluding C. difficile, with an initial dose of 4 mg orally, then 2 mg every 2 hours (maximum 16 mg/day) 6, 7
For refractory diarrhea, octreotide 500 μg subcutaneously three times daily can be used, with a titrated dose upward if no response to initial dosing 6, 7, 8

Patients with severe diarrhea persisting >48 hours despite antimotility agents should be admitted to the hospital 6, 7, 8

Immunocompromised patients should avoid probiotics due to limited safety data and risk of fungemia/bacteremia 6, 7, 8

The use of probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus) may reduce the incidence of antibiotic-associated diarrhea in immunocompetent patients, but evidence quality is limited 6, 7, 8